CTI BioPharma Announces Closing of Rights Offering
Of the total shares of Common Stock and Series X Preferred sold and issued in the Rights Offering, certain affiliates of
The Rights Offering was made pursuant to
About CTI BioPharma Corp.
CTI BioPharma Corp. is a biopharmaceutical company focused on the acquisition, development and commercialization of novel targeted therapies for blood-related cancers that offer a unique benefit to patients and their healthcare providers. In particular,
CTI BioPharma Investor Contacts:
View original content to download multimedia:http://www.prnewswire.com/news-releases/cti-biopharma-announces-closing-of-rights-offering-301019300.html